Introduction {#section1-2151458517716516}
============

Geriatric hip fractures are an increasing burden as the world population ages. The consequences of hip fractures include high mortality,^[@bibr1-2151458517716516][@bibr2-2151458517716516]-[@bibr3-2151458517716516]^ long-term disabilities^[@bibr1-2151458517716516],[@bibr4-2151458517716516]^ and decreased quality of life,^[@bibr1-2151458517716516]^ and high costs of care.^[@bibr3-2151458517716516]^

According to a consensus statement, geriatricians may provide the greatest benefit when caring for the most vulnerable older adults,^[@bibr5-2151458517716516]^ such as those with hip fracture. To compliment surgical care, various models of multidisciplinary care for patients have been developed.^[@bibr6-2151458517716516]^ Current literature suggests the use of a comprehensive care approach to decrease mortality in a randomized setting,^[@bibr7-2151458517716516]^ in a dedicated hip fracture unit^[@bibr8-2151458517716516]^ and in register-based studies.^[@bibr9-2151458517716516]^ On the other hand, implementation of a clinical pathway with a standardized set of orders^[@bibr10-2151458517716516]^ or including an inpatient geriatric consultation team in the care model^[@bibr11-2151458517716516]^ demonstrated no effect on mortality. A protocol-driven comanaged comprehensive care system combining a clinical pathway and geriatric care also reduces mortality^[@bibr12-2151458517716516]^ but not without the involvement of a geriatrician.^[@bibr13-2151458517716516]^

The implementation and components of orthogeriatric care models vary,^[@bibr6-2151458517716516],[@bibr10-2151458517716516]^ making it challenging to compare different models. The background components of effective orthogeriatric care are not very well understood or researched.^[@bibr14-2151458517716516]^ In addition, older hip fracture patients are a heterogeneous group^[@bibr15-2151458517716516],[@bibr16-2151458517716516]^ and the beneficial actions of care and rehabilitation requirements may vary, which further complicates studies of optimal orthogeriatric models.

Moving forward, given the increasing number of hip fractures, limited health-care resources, and the short supply of geriatricians, there is a pressing need to clarify what truly is effective orthogeriatric care. In order to increase equity and effectiveness, targeted and tailored services may be needed. We examined the association of patient-related factors with the effect of an in-hospital comprehensive geriatric assessment (CGA; [Table 1](#table1-2151458517716516){ref-type="table"}) on 1-month mortality among older hip fracture patients in an orthopedic ward during implementation of orthogeriatric hip fracture program (HFP).

###### 

Summary of Current Components of Seinäjoki Central Hospital Hip Fracture Program (HFP).

![](10.1177_2151458517716516-table1)

+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Components For All Patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Components of comprehensive geriatric assessment (CGA; when available**)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
+=====================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================+=========================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================+
| Standardized and detailed set of orders on-- Examining and imaging-- Pain management-- Fluid balance and nutritional care with supplements-- Type of anesthesia (mainly spinal)-- Surgical care for different fracture types-- Delirium prevention and management-- Oxygen therapy-- Erythrocyte transfusion thresholds of hemoglobin-- Urinary catheterization practices (removed on 1. postoperative day)-- Mobilizing and physiotherapy-- Deep venous thrombosis prophylaxis                                                                                     | Interdisciplinary orthogeriatric ward rounds on weekdays-- Staff: geriatrician (or a resident), orthopedic hip fracture nurse, physiotherapist-- Encouragement and motivation of the patient-- Check-up on the adherence to standardized orders of care protocol-- Early detection and treatment of complications-- Patient examination: orthostatic blood pressure test, oxygen saturation, orientation, auscultation of cardiac, and pulmonary sounds, any additional examination as needed, evaluation of mobility-- Mobilizing the patient-- Setting the goal for rehabilitation-- Careful evaluation and adjustment of medications-- Evaluation of calcium and vitamin D intake and supplements-- Orders on examinations needed after discharge (for example, on memory disorder and osteoporosis) |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Preround interview by a geriatric hip fracture nurse-- Living arrangements and the level of assistance needed before the fracture-- Mobility level and walking aids before the fracture-- Diagnosis of a memory disease or any concern of cognitive decline (prefracture Mini-Mental Status Examination score, if available)-- Detailed information of circumstances of the fall-- Mini-Nutritional Assessment, estimated height, weight and body mass index-- Calcium intake (dietary and supplements) and vitamin D supplementation-- Consent for data collection | Instructions and suggestions to discharge destination-- Objectives of treatment and rehabilitation-- Physical status at discharge-- General instructions on mobilizing (including active walking exercises, encouragement toward independency)-- Nutritional plan including supplements-- Medications plan and instructions on discontinuation of opiate pain medications-- Planned examinations and follow-ups after discharge-- Separate discharge documents from all disciplines (geriatrician, orthopedic, nurse, and physiotherapist)                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Discharge Criteria-- Stable hemodynamics (oxygen saturation, pulse, and blood pressure, cardiac rhythm)-- Hemoglobin \> 90 g/L (\>100 g/L if severe cardiac condition)-- Urinary catheter removed-- Pain under control-- Patient mobilized-- Medications updated to the outpatient file-- If treated for infection, declining C-reactive protein (CRP) and fever-- 2nd or later postoperative day-- No discharge of a patient with immediate poor prognosis                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

Methods {#section2-2151458517716516}
=======

Study Population {#section3-2151458517716516}
----------------

This is a retrospectively analyzed study of prospectively collected, population-based data on 1445 consecutive hip fracture patients aged ≥ 65 years having their first hip fracture between September 2007 and August 2014. The final study population comprised 1425 hip fracture patients as 20 (1.4%) patients declined participation in the study. Pathologic and periprosthetic fractures were excluded. The data were collected at Seinäjoki Central Hospital, Finland, which is the only hospital that provides acute surgical care in the Hospital District of Southern Ostrobothnia, which has a population of 199 000.

Hip Fracture Program and Study Design {#section4-2151458517716516}
-------------------------------------

Hip fracture program was first initiated in our hospital in 2007 with the goal of improving the care of hip fracture patients in accordance with evidence-based guidelines. First, a database with demographic, medical, surgical, functional, social, and outcome measures was established. Geriatrician-led interdisciplinary rounds began in 2008. A multidisciplinary orthogeriatric committee was established in 2009 and includes physicians from geriatrics, anesthesia, and orthopedic surgery; nurses from the orthopedic ward; and physiotherapists. Other experts are consulted if needed. The first written HFP with a standardized set of orders for hip fracture patients' hospital stay was delivered in 2009. The integrated care model is of shared care: Patients are within an orthopedic ward, but the responsibility for the care of the patient is shared between the orthopedic surgeon and the geriatrician. The orthopedic surgeon sees the patient daily and the geriatrician on weekdays, and both services write their own orders. Resident physicians provide some of the care in this model as well.

Since its initiation, the HFP has widely expanded and is regularly updated by the orthogeriatric committee, and it has been stabilized from a project to a permanent model of care. The 2013 update of the HFP includes extensive instructions on pre-, peri-, postoperative, and surgical care and CGA, discharge criteria, and recommendations for postdischarge care ([Table 1](#table1-2151458517716516){ref-type="table"}). The emphasis is on detailed, individually adjusted, and multidisciplinary care throughout and after the hospitalization. The physicians and nurses are encouraged to focus on the HFP through continuous education. A dedicated orthogeriatric nurse coordinates the service in the orthopedic ward.

The HFP was developed and implemented in a real-life setting with minimal additional resources. There are only a few posts for geriatricians in our hospital, and, like in many regions in Finland, occasional shortage of geriatricians has occurred. As a consequence of this, CGA has not been performed at all times. However, when a geriatrician is available, every hip fracture patient in the orthopedic ward receives CGA without any patient selection by exclusion or inclusion criteria. In the present study, we compared the effect of receiving CGA versus not receiving CGA while hospitalized for hip fracture on 1-month mortality during implementation of the HFP. To identify the specific patient-related factors affecting mortality when combined with CGA, we examined the association of baseline characteristics with the effect of CGA on mortality. By CGA, we mean the components of care as presented in [Table 1](#table1-2151458517716516){ref-type="table"}.

Data Collection {#section5-2151458517716516}
---------------

During hospitalization, the patients' medical records and interview conducted by a nurse with the patient or a caregiver were used. Data were collected on age, sex, fracture type, American Society of Anesthesiology (ASA) score, on-admission serum creatinine, number of regularly taken medications, regular or as-needed use of hypnotic benzodiazepines and z-hypnotics (BZD-Z; midazolam, temazepam, nitrazepam, triazolam, zaleplon, zolpidem, and zopiclon), prefracture diagnosis of memory disorder, prefracture mobility level and living arrangements, and receiving or not receiving CGA. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to calculate estimated glomerular filtration rate (eGFR). The results were categorized into 4 groups: ≥ 60 mL/min/1.73 m^2^ (normal to mildly decreased eGFR~CKD-EPI~), 45 to 59 mL/min/1.73 m^2^ (mildly to moderately decreased eGFR~CKD-EPI~), 30 to 44 mL/min/1.73 m^2^ (moderately to severely decreased eGFR~CKD-EPI~), and under 30 mL/min/1.73 m^2^ (severely decreased eGFR~CKD-EPI~ or kidney failure). The dates of death were provided by the National Population Register Center and extracted from the electronic patient files of the hospital. There were no losses to mortality follow-up.

Statistical Analyses {#section6-2151458517716516}
--------------------

The distribution of patient-related factors in case numbers and percentages according to the CGA were calculated. Differences were tested using Pearson χ^2^ test or Fisher exact test ([Table 2](#table2-2151458517716516){ref-type="table"}). One-month (1-30 days from hip fracture) mortality was analyzed by age- and sex-adjusted Cox proportional hazards models ([Table 3](#table3-2151458517716516){ref-type="table"}). Age- and sex-adjusted association of receiving versus not receiving CGA with mortality separately in each group of the patient-related factors were performed using the Cox proportional hazards model showing results by hazard ratios with 95% confidence intervals ([Table 4](#table4-2151458517716516){ref-type="table"}). One-month mortality was illustrated by a survival curve ([Figure 1](#fig1-2151458517716516){ref-type="fig"}). A *P* value of \<.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS for Windows, version 23.0 (IBM Corp, Armonk, New York).

###### 

Distribution of the Patient-Related Factors and Outcome Variables According to Comprehensive Geriatric Assessment.^a,b^

![](10.1177_2151458517716516-table2)

  Patient-related factors                        Total       Comprehensive geriatric assessment   *P* Value   
  ---------------------------------------------- ----------- ------------------------------------ ----------- ----------
  Age, n (%)                                                                                                  .268
   65-79                                         410 (29)    247 (28)                             163 (30)    
   80-89                                         759 (53)    469 (53)                             290 (54)    
   90 or over                                    256 (18)    170 (19)                             86 (16)     
  Sex, n (%)                                                                                                  .707
   Women                                         1062 (75)   657 (74)                             405 (75)    
   Men                                           363 (26)    229 (26)                             134 (25)    
  ASA score, n (%)                                                                                            **.002**
   1-3                                           1047 (74)   672 (76)                             375 (70)    
   4-5                                           354 (25)    206 (23)                             148 (28)    
  Number of regularly taken medications, n (%)                                                                .097
   \< 4                                          247 (17)    154 (17)                             93 (17)     
   4-10                                          916 (64)    554 (63)                             362 (67)    
   \> 10                                         261 (18)    177 (20)                             84 (16)     
  BZD-Z                                                                                                       .153
   No                                            1033 (73)   655 (74)                             378 (70)    
   Yes                                           391 (27)    230 (26)                             161 (30)    
  Diagnosis of memory disorder, n (%)                                                                         .272
   No                                            1038 (73)   635 (72)                             403 (75)    
   Yes                                           379 (27)    247 (28)                             132 (25)    
  eGFR~CKD-EPI~, n (%)                                                                                        .167
   \> 60 mL/min/1.73m^2^                         821 (58)    490 (55)                             331 (61)    
   45-59 mL/min/1.73m^2^                         287 (29)    194 (22)                             93 (17)     
   30-44 mL/min/1.73m^2^                         193 (14)    125 (14)                             68 (13)     
   \< 30 mL/min/1.73m^2^                         87 (6)      55 (6)                               32 (6)      
  Mobility level, n (%)                                                                                       .070
   Outdoors unassisted                           743 (52)    467 (53)                             276 (51)    
   Indoors unassisted                            557 (41)    354 (40)                             223 (41)    
   Assisted only                                 70 (5)      46 (5)                               24 (5)      
   Unable to walk                                25 (2)      17 (2)                               8 (2)       
  Living arrangements, n (%)                                                                                  **.002**
   Home                                          565 (40)    362 (41)                             203 (38)    
   Home with organized homecare                  399 (28)    235 (27)                             164 (30)    
   Assisted living accommodation                 237 (17)    136 (15)                             101 (19)    
   Institutionalized                             213 (15)    150 (17)                             62 (12)     
  Fracture type, n (%)                                                                                        .545
   Neck of femur                                 886 (62)    541 (61)                             345 (64)    
   Intertrochanteric                             458 (32)    292 (33)                             166 (31)    
   Subtrochanteric                               80 (6)      52 (6)                               28 (5)      

Abbreviations: ASA, American Society of Anesthesiologists; BZD-Z, hypnotic benzodiazepines and z-hypnotics (midazolam, temazepam, nitrazepam, triazolam, zaleplon, zolpidem, and zopiclon); eGFR~CKD-EPI~, estimated glomerular filtration rate calculated by the Chronic Kidney Disease Epidemiology Collaboration equation.

^a^n = 1425.

^b^Missing values are not shown but were tested and included in the percentages. Differences between groups were tested by Pearson χ^2^ test or Fisher exact test. Statistically significant *P* values (*P* \< .05) are bolded.

###### 

Distribution and Associations of the Patient-Related Factors and Comprehensive Geriatric Assessment According to 1-month Mortality.^a^
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  Patient-related factors                 1-Month Mortality             
  --------------------------------------- ------------------- --------- -------------------
  Age                                                                   
   65-79                                  389 (30)            21 (15)   1.00
   80-89                                  683 (53)            76 (54)   2.21 (1.36-3.59)
   90 or over                             213 (17)            43 (31)   3.87 (2.28-6.55)
  Sex                                                                   
   Women                                  970 (76)            92 (66)   1.00
   Men                                    315 (25)            48 (34)   1.80 (1.26-2.45)
  ASA score                                                             
   1-3                                    983 (77)            64 (46)   1.00
   4-5                                    290 (23)            64 (46)   2.75 (1.94-3.91)
  Number of regularly taken medications                                 
   \< 4                                   236 (18)            11 (8)    1.00
   4-10                                   832 (65)            84 (60)   1.94 (1.03-3.63)
   \> 10                                  217 (17)            44 (32)   3.67 (1.89-7.12)
  BZD-Z                                                                 
   No                                     937 (73)            96 (69)   1.00
   Yes                                    348 (27)            43 (31)   1.09 (0.76 -1.56)
  Diagnosis of memory disorder                                          
   No                                     952 (74)            86 (61)   1.00
   Yes                                    330 (26)            49 (35)   1.55 (1.09-2.20)
  eGFR~CKD-EPI~                                                         
   \> 60 mL/min/1.73m^2^                  766 (60)            55 (39)   1.00
   45-59 mL/min/1.73m^2^                  252 (20)            35 (25)   1.69 (1.10-2.59)
   30-44 mL/min/1.73m^2^                  164 (13)            29 (21)   1.93 (1.22-3.07)
   \< 30 mL/min/1.73m^2^                  69 (5)              18 (13)   2.99 (1.75-5.12)
  Mobility level                                                        
   Outdoors unassisted                    718 (56)            25 (18)   1.00
   Indoors unassisted                     486 (38)            91 (65)   4.63 (2.95-7.28)
   Assisted only                          58 (5)              12 (9)    4.77 (2.38-9.59)
   Unable to walk                         21 (2)              4 (3)     4.04 (1.40-11.7)
  Living arrangements                                                   
   Home                                   543 (42)            22 (16)   1.00
   Home with organized homecare           369 (29)            30 (21)   1.79 (1.02-3.14)
   Assisted living accommodation          197 (15)            40 (29)   3.97 (2.31-6.81)
   Institutionalized                      169 (13)            44 (31)   5.08 (2.98-8.65)
  Fracture type                                                         
   Neck of femur                          800 (62)            86 (61)   1.00
   Intertrochanteric                      410 (32)            48 (34)   0.99 (0.69 -1.41)
   Subtrochanteric                        74 (6)              6 (4)     0.65 (0.28 -1.49)
  Comprehensive Geriatric Assessment                                    
   No                                     474 (37)            65 (46)   1.00
   Yes                                    811 (63)            75 (54)   0.63 (0.45-0.87)

Abbreviations: ASA, American Society of Anesthesiologists, BZD-Z, hypnotic benzodiazepines and z-hypnotics (midazolam, temazepam, nitrazepam, triazolam, zaleplon, zolpidem, and zopiclon), CI, confidence interval; eGFR~CKD-EPI~, estimated glomerular filtration rate calculated by the Chronic Kidney Disease Epidemiology Collaboration equation; HR, hazard ratio.

^a^n = 1425.

^b^Missing values are not shown but were tested and included in the percentages. Associations with mortality were tested by Cox hazard regression models showing results by HRs and 95% CIs.

###### 

Age- and Sex-Adjusted Effect of In-hospital CGA (Total n = 1425, CGA n = 886, no CGA n = 539) on Mortality 1 Month After Hip Fracture in the Groups of Patient-Related Factors.^a^
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                                                 Mortality Ratio at 1 Month Comparing Groups of CGA versus non-CGA (Total Deaths n=140)              
  --------------------------------------- ------ ---------------------------------------------------------------------------------------- ---------- ---------------
  Age                                                                                                                                                
   65-79                                  410    21 (5.1)                                                                                 0.74       0.31-1.75
   80-89                                  759    76 (10.0)                                                                                **0.46**   **0.29-0.73**
   90 or over                             256    43 (16.8)                                                                                0.98       0.52-1.85
  Sex                                                                                                                                                
   Women                                  1062   92 (8.7)                                                                                 **0.57**   **0.38-0.86**
   Men                                    363    48 (13.2)                                                                                0.76       0.42-1.34
  ASA                                                                                                                                                
   1-3                                    1047   64 (6.1)                                                                                 **0.60**   **0.37-0.99**
   4-5                                    354    64 (18.1)                                                                                0.86       0.53-1.42
  Number of regularly taken medications                                                                                                              
   \< 4                                   247    11 (4.5)                                                                                 0.58       0.17-1.96
   4-10                                   916    84 (9.2)                                                                                 **0.59**   **0.38-0.91**
   \> 10                                  261    44 (16.9)                                                                                **0.58**   **0.32-1.06**
  BZD-Z                                                                                                                                              
   No                                     1033   97 (9.4)                                                                                 0.75       0.50-1.13
   Yes                                    391    43 (11.0)                                                                                **0.38**   **0.21-0.73**
  Diagnosis of memory disorder                                                                                                                       
   No                                     1038   86 (8.3)                                                                                 0.70       0.46-1.07
   Yes                                    379    49 (12.9)                                                                                **0.50**   **0.29-0.88**
  eGFR~CKD-EPI~                                                                                                                                      
   \> 60 mL/min/1.73m^2^                  821    55 (6.7)                                                                                 0.73       0.43-1.24
   45-59 mL/min/1.73m^2^                  287    35 (12.2)                                                                                **0.46**   **0.24-0.90**
   30-44 mL/min/1.73m^2^                  193    29 (15.0)                                                                                0.79       0.36-1.72
   \< 30 mL/min/1.73m^2^                  87     18 (20.7)                                                                                **0.28**   **0.10-0.76**
  Mobility level                                                                                                                                     
   Outdoors unassisted                    743    25 (3.4)                                                                                 0.52       0.24-1.14
   Indoors unassisted                     557    91 (16.3)                                                                                0.75       0.49-1.14
   Assisted only                          70     12 (17.1)                                                                                0.77       0.24-2.42
   Unable to walk                         25     4 (16.0)                                                                                 2.32       0.10-53.4
  Living arrangements                                                                                                                                
   Home                                   565    22 (3.9)                                                                                 0.75       0.32-1.75
   Home with organized homecare           399    30 (7.5)                                                                                 0.81       0.39-1.69
   Assisted living accommodation          237    40 (16.9)                                                                                **0.40**   **0.21-0.76**
   Institutionalized                      213    44 (20.7)                                                                                0.73       0.39-1.37
  Fracture type                                                                                                                                      
   Neck of femur                          886    86 (9.7)                                                                                 **0.44**   **0.29-0.68**
   Intertrochanteric                      458    48 (10.5)                                                                                1.20       0.65-2.21
   Subtrochanteric                        80     6 (7.5)                                                                                  0.50       0.10-2.48

Abbreviations: ASA, American Society of Anesthesiologists, BMI, body mass index; BZD-Z, hypnotic benzodiazepines and z-hypnotics (midazolam, temazepam, nitrazepam, triazolam, zaleplon, zolpidem, and zopiclon), eGFR~CKD-EPI,~ estimated glomerular filtration rate calculated by the Chronic Kidney Disease Epidemiology Collaboration equation.

^a^Statistically significant *P* values (*P* \< .10) are bolded.

![One-month survival after hip fracture according to comprehensive geriatric assessment by age- and sex-adjusted Cox proportional hazard model.](10.1177_2151458517716516-fig1){#fig1-2151458517716516}

Ethical Consideration {#section7-2151458517716516}
---------------------

The study was performed according to the 1964 Helsinki declaration and its later amendments and approved by the Ethics Committee of the Hospital District of South Ostrobothnia. Written informed consent was obtained from the participants or their caregivers.

Results {#section8-2151458517716516}
=======

Data on 1425 hip fracture patients were available ([Tables 2](#table2-2151458517716516){ref-type="table"} and [3](#table3-2151458517716516){ref-type="table"}). The median age was 84 years (interquartile range: 78-88, range: 65-104), and the median length of stay was 6 days (interquartile range: 5-7, range: 1-37). Of the 1425 patients, 886 (62%) received CGA during hospitalization. Of the patients, 36 (3%) patients died during acute hospitalization and 140 (10%) patients within 1 month. Of the patients receiving CGA, 8.5% died within 1 month of the hip fracture, compared to 12.0% of the patients not receiving CGA (*P* = .028).

Comprehensive Geriatric Assessment {#section9-2151458517716516}
----------------------------------

The patients receiving CGA while hospitalized, compared to those who did not, more likely had an ASA score of 1 to 3 (*P* = .002) and lived at home or in an institution (*P* = .002). Age, sex, number of regularly taken medications, use of BZD-Zs, diagnosis of memory disease, eGFR~CKD-EPI~, prefracture mobility level, or fracture type were not significantly different between the 2 groups ([Table 2](#table2-2151458517716516){ref-type="table"}).

Age- and Sex-Adjusted 1-Month Mortality {#section10-2151458517716516}
---------------------------------------

In the age- and sex-adjusted Cox regression analysis, patients with older age, higher ASA score, higher number of medications in regular use, having a diagnosis of memory disease, lower eGFR~CKD-EPI~, living in more supported living accommodations, having lower mobility class, and male sex had a greater likelihood of dying within 1 month of the hip fracture ([Table 3](#table3-2151458517716516){ref-type="table"}). The patients receiving CGA were significantly more likely to survive at 1 month after the hip fracture than those not receiving CGA ([Table 3](#table3-2151458517716516){ref-type="table"}). The survival curve is shown in [Figure 1](#fig1-2151458517716516){ref-type="fig"}.

Age- and Sex-Adjusted Analyses of the Effect of CGA With Mortality in the Groups of Patient-Related Factors {#section11-2151458517716516}
-----------------------------------------------------------------------------------------------------------

In the age- and sex-adjusted Cox proportional hazards model, CGA was significantly associated with decreased risk of 1-month mortality in patients aged 80 to 89 years, female sex, ASA score 1 to 3, using regular or as-needed BZD-Zs, having a diagnosis of memory disease, taking 4 to 10 medications daily, having eGFR~CKD-EPI~ 45 to 59 mL/min/1.73, m^2^ or \< 30 mL/min/1.73 m^2^, living in an assisted-living accommodation, or having the fracture in the neck of the femur ([Table 4](#table4-2151458517716516){ref-type="table"}).

Discussion {#section12-2151458517716516}
==========

Based on our findings, receiving CGA while hospitalized for hip fracture was associated with decreased 1-month mortality. This corroborates with previous literature of HFPs having a protective impact on short-term mortality^[@bibr7-2151458517716516][@bibr8-2151458517716516]-[@bibr9-2151458517716516],[@bibr12-2151458517716516]^ Moreover, our study revealed several potentially medically modifiable factors and factors related to prefracture patient characteristics that could explain the protective effect of in-hospital CGA on short-term mortality.

In this study, patients aged 80 to 89 years benefitted from the CGA in relation to mortality, whereas younger or older patients did not. Older age is a well-known risk factor for mortality after hip fracture.^[@bibr2-2151458517716516],[@bibr17-2151458517716516]^ Younger hip fracture patients are less frail^[@bibr15-2151458517716516]^ and more likely to survive the hip fracture regardless of CGA. Nonagenarians with hip fracture are high-risk patients and are more often anemic and have more adverse events while hospitalized.^[@bibr17-2151458517716516]^ In our study, CGA was associated with decreased mortality in women but not in men. Although women suffering hip fracture are older,^[@bibr18-2151458517716516]^ male hip fracture patients have more chronic comorbidities,^[@bibr18-2151458517716516]^ more severe health conditions, and a higher risk of complications during hospitalization for hip fracture.^[@bibr19-2151458517716516]^ In addition, male sex itself is a risk factor for mortality in this patient group.^[@bibr2-2151458517716516]^ It might be that in women, the conditions leading to hip fracture that are more of a concern are general frailty, including many potentially modifiable factors, in which case CGA can be more valuable in relation to mortality. The findings also imply that older men require specific attention regarding hip fracture care. According to the ASA classification, the general health of patients with a score of 1 to 3 varies from healthy to having severe systemic disease.^[@bibr20-2151458517716516]^ Based on our results, the survival potential of these patients was better when CGA was performed.

An important part of the CGA is careful and critical evaluation of the patients' medications. Our findings revealed that patients taking 4 to 10 regular medications or using BDZ-Z benefitted from CGA in relation to mortality. In a recent study by Gosch et al, only 9.6% of the hip fracture patients were taking appropriate medications.^[@bibr21-2151458517716516]^ High number of medications^[@bibr22-2151458517716516]^ and use of BZDs^[@bibr23-2151458517716516]^ are associated with chronic illnesses, which increase the importance of input from a geriatrician. Renal insufficiency, such as multiple medication use, might be one of the few modifiable risk factors, as the patients with even severe renal insufficiency (eGFR~CKD-EPI~ \< 30 mL/min/1.73m^2^) on admission showed improved survival if assessed by a geriatrician. This might be partly due to a synergistic effect with a medication evaluation because the prevalence of potentially inappropriate medications in older patients with chronic kidney disease is high.^[@bibr24-2151458517716516]^ The protective association of CGA in patients with renal dysfunction may also be explained by more careful fluid therapy. Dehydration is common among hip fracture patients and may increase the risk of acute renal dysfunction with a potentially poor prognosis.^[@bibr25-2151458517716516]^

During the HFP, CGA was associated with decreased mortality among patients with a prefracture-diagnosed memory disorder. Dementia is a well-known risk factor for mortality among hip fracture patients.^[@bibr2-2151458517716516]^ Orthogeriatric programs not excluding cognitively impaired patients have been successful in reducing in-hospital^[@bibr7-2151458517716516]^ and 1-year^[@bibr8-2151458517716516]^ mortality. In a subgroup analysis of hip fracture patients with dementia, the intervention group experienced fewer complications and better functional recovery, but the multidisciplinary intervention program had no effect on mortality.^[@bibr26-2151458517716516]^ Poor knowledge of the engagement and recovery capacity of patients with dementia affects their access to rehabilitation after hip fracture,^[@bibr27-2151458517716516]^ and this may also impact acute care decisions. A geriatric approach includes individual consideration for each patient and no denial of treatment or rehabilitation based merely on a diagnosis of dementia. Furthermore, dementia is an independent risk factor for iatrogenic conditions such as delirium^[@bibr28-2151458517716516]^ in hip fracture patients. An optimistic attitude combined with professional care, including delirium prevention,^[@bibr6-2151458517716516]^ may explain some of the results of our study.

Patients living in assisted-living accommodations are too frail to survive at home but well enough to avoid institutional living. In our study, this patient group benefitted greatly from CGA with regard to mortality. Community-dwelling hip fracture patients are generally younger and fitter^[@bibr29-2151458517716516]^ and therefore may have a better prognosis regardless of the geriatrician's input. Patients living in long-term residential care are generally in worse health and are thus more likely to have a poorer outcome,^[@bibr30-2151458517716516]^ and the geriatricians' principal role is to ensure quality of care toward the end of life.

In the present study, CGA was associated with improved short-time survival when the patients had a femoral neck fracture. Patients experiencing other fracture types are older,^[@bibr17-2151458517716516],[@bibr31-2151458517716516]^ have more comorbidities,^[@bibr31-2151458517716516]^ and a higher risk of mortality^[@bibr2-2151458517716516],[@bibr31-2151458517716516]^ which may determine the prognosis beyond the effects of CGA.

One of the main strengths of the study is the prospective and population-based design. Also, the data were collected systematically and almost entirely by 1 individual. In addition, cognitive impairment and institutional living were not exclusion criteria, which increases the generalizability of the study. The study also has limitations. Due to the observational and noninterventional nature of this real-life study, there may be some uncertainty in the results. Toward the end of the study time, HFP has become more comprehensive and staff more experienced. Furthermore, there has been secular change toward overall increase in the awareness of the needs of this specific population. Also, although being otherwise similar, the groups receiving versus not receiving CGA differed significantly by the ASA scores and living arrangements. This is due to the fact that the groups were not predetermined or counterbalanced but were formed based on day-to-day availability of a geriatrician and without preselection of patients. Further studies are warranted to examine whether the findings observed in the present study also apply to other outcomes such as readmissions, mobility and living arrangements, and on mortality in longer term. We believe that a somewhat longer centralized acute postoperative period and rehabilitation in a dedicated orthogeriatric unit with in-hospital CGA is needed to further improve the outcomes.

In conclusion, the observation in our study of the protective association of in-hospital CGA in patients with multiple medications and renal insufficiency with hip fracture mortality highlights the significance of comprehensive and proactive medical assessment and interventions as fundamental part of acute orthogeriatric care. The orthogeriatric approach for younger and fitter patients did not have an effect on short-time mortality. Also, in relation to mortality, the oldest and frailest patients with the worst prognosis did not benefit of it either. These patients are, however, at the core of geriatric know-how,^[@bibr5-2151458517716516]^ and the quality of care for those patients that are toward the end of life should be improved by having a geriatrician in the hip fracture team. After all, HFPs aim not only at reducing mortality but also at improving the quality of care.^[@bibr10-2151458517716516],[@bibr12-2151458517716516]^ Between the extremes of low-risk and high-risk patients is a large group of patients whose potential to survive might go unnoticed in traditional care. Including a geriatrician and a CGA in the HFP can actually save the lives of these patients.

**Authors' Note:** The data sets supporting the conclusions of this article are not available in an open access repository because the data sets contain information by which the participants may be directly or indirectly identified. Informed consent from participants and the approval by the Ethics Committee of the Hospital District of South Ostrobothnia was obtained for publication of study results, but not for the publication of patient raw-data separately. Further, the data used in this study are a part of a clinical quality register of Seinäjoki Central Hospital and is continuously being updated. If anyone is interested in exploring specific issue, please contact Maria S. Nuotio, MD, PhD. Email: <maria.nuotio@epshp.fi>. Tel. +358-6-41533179.
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